Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Suvorexant

FDA-approved product (tablet, oral), marketed as Belsomra.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Suvorexant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Insomnia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Orexin receptor antagonists
FDA pharmacologic class
Orexin Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Suvorexant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.6 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Suvorexant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant

    NCT03755310 · start 2019-02

    Registered record
    Registry ID
    NCT03755310
    Conditions
    Restless Legs Syndrome
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-02
    Completion
    2020-03
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRestless Legs Syndrome
    InterventionSuvorexant; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users

    NCT03657355 · start 2018-09-07

    Registered record
    Registry ID
    NCT03657355
    Conditions
    Healthy Recreational Drug Users
    Interventions
    ACT-541468; Suvorexant; Zolpidem; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-09-07
    Completion
    2019-08-08
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Recreational Drug Users
    InterventionACT-541468; Suvorexant; Zolpidem; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

    NCT03312517 · start 2018-04-15

    Registered record
    Registry ID
    NCT03312517
    Conditions
    Insomnia
    Interventions
    Suvorexant 10 mg; Suvorexant 20 mg; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-04-15
    Completion
    2018-10-25
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionSuvorexant 10 mg; Suvorexant 20 mg; Placebo oral capsule
    PhasePhase 4
    Registry statusCompleted

  • Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia

    NCT03034018 · start 2017-05-25

    Registered record
    Registry ID
    NCT03034018
    Conditions
    Insomnia
    Interventions
    suvorexant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-05-25
    Completion
    2020-04-03
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    Interventionsuvorexant; placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users

    NCT03158025 · start 2017-04-19

    Registered record
    Registry ID
    NCT03158025
    Conditions
    Insomnia Disorders
    Interventions
    Zolpidem tablets; Suvorexant tablets, over-encapsulated; Lemborexant tablets; Placebo lemborexant; Placebo zolpidem; Placebo suvorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-04-19
    Completion
    2018-07-04
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia Disorders
    InterventionZolpidem tablets; Suvorexant tablets, over-encapsulated; Lemborexant tablets; Placebo lemborexant +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia

    NCT03110315 · start 2017-03-28

    Registered record
    Registry ID
    NCT03110315
    Conditions
    Multiple Sclerosis; Fatigue; Insomnia
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-03-28
    Completion
    2022-03-21
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Fatigue; Insomnia
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

    NCT02669030 · start 2017-03-01

    Registered record
    Registry ID
    NCT02669030
    Conditions
    Depression; Major Depressive Disorder; MDD; Insomnia
    Interventions
    suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-03-01
    Completion
    2019-12
    Enrolment
    74

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression; Major Depressive Disorder; MDD; Insomnia
    Interventionsuvorexant; Placebo
    PhasePhase 4
    Registry statusUnknown

  • To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia

    NCT02849184 · start 2017-01-17

    Registered record
    Registry ID
    NCT02849184
    Conditions
    Hypertension; Insomnia
    Interventions
    suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-17
    Completion
    2018-03
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Insomnia
    Interventionsuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder

    NCT02849548 · start 2017-01-03

    Registered record
    Registry ID
    NCT02849548
    Conditions
    Posttraumatic Stress Disorder
    Interventions
    suvorexant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-01-03
    Completion
    2021-05-19
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPosttraumatic Stress Disorder
    Interventionsuvorexant; placebo
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)

    NCT02750306 · start 2016-05-23

    Registered record
    Registry ID
    NCT02750306
    Conditions
    Sleep Initiation and Maintenance Disorders; Alzheimer Disease
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-05-23
    Completion
    2018-09-30
    Enrolment
    285

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders; Alzheimer Disease
    InterventionSuvorexant; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Suvorexant and Trauma Related Insomnia

    NCT02704754 · start 2016-05-01

    Registered record
    Registry ID
    NCT02704754
    Conditions
    Insomnia; Posttraumatic Stress Disorder
    Interventions
    suvorexant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-05-01
    Completion
    2021-04-30
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Posttraumatic Stress Disorder
    Interventionsuvorexant; placebo
    PhasePhase 4
    Registry statusCompleted

  • Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers

    NCT02491788 · start 2016-02-01

    Registered record
    Registry ID
    NCT02491788
    Conditions
    Sleep Disorder, Shift-Work
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-02-01
    Completion
    2019-08-01
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Disorder, Shift-Work
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Suvorexant in Insomnia Co-morbid With Fibromyalgia

    NCT02684136 · start 2016-02-01

    Registered record
    Registry ID
    NCT02684136
    Conditions
    Insomnia; Fibromyalgia
    Interventions
    suvorexant; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2016-02-01
    Completion
    2018-07-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Fibromyalgia
    Interventionsuvorexant; placebo
    PhasePhase 4
    Registry statusTerminated

  • Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder

    NCT02527564 · start 2015-09

    Registered record
    Registry ID
    NCT02527564
    Conditions
    Insomnia; Bipolar Disorder
    Interventions
    Suvorexant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-09
    Completion
    2021-03-01
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Bipolar Disorder
    InterventionSuvorexant; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

    NCT01311882 · start 2011-04

    Registered record
    Registry ID
    NCT01311882
    Conditions
    Insomnia
    Interventions
    MK-4305 40 mg; MK-4305 20 mg; Zopiclone; Grossly Matching Placebo for Zopiclone; Matching Placebo for MK-4305
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2011-11
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia
    InterventionMK-4305 40 mg; MK-4305 20 mg; Zopiclone; Grossly Matching Placebo for Zopiclone +1 more
    PhasePhase 1
    Registry statusCompleted